Cargando…
PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.
Autores principales: | Saavedra, Minerva Montalvo, Garcia, Alvaro Bienert, Pérez-Pinilla, Belén, González-Casanova, Paula Reyes, Díaz-Lopez, Marta, Quiroz, Jose Gregorio Torres, Llorens, Alberto Martinez, Goyeneche, Cielo de Los Ángeles Lorena Borja, Higueras, Carolina Lacalzada, González, Bernardo Javier González, Garcia, Miguel Teodoro Hernandez, Lakhwani, Sunil Lakhwani |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430116/ http://dx.doi.org/10.1097/01.HS9.0000974424.53907.97 |
Ejemplares similares
-
Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
por: Ferrara, Felicetto
Publicado: (2020) -
Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021) -
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022) -
Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020) -
AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax
por: Low, Soon Khai, et al.
Publicado: (2022)